Standardgruppe |
Mi
| 05.03.2025 | 14:00 | 16:15 | SR 62 - Mittel frontal (MC2.Q.01.019) | Abhaltung | fix | Update viral hepatitis and HIV |
| |
Mi
| 05.03.2025 | 16:30 | 18:45 | SR 62 - Mittel frontal (MC2.Q.01.019) | Abhaltung | fix | Diagnostics of viral diseases |
| |
Do
| 06.03.2025 | 08:30 | 10:45 | SR 62 - Mittel frontal (MC2.Q.01.019) | Abhaltung | fix | Molecular Diagnostics |
| |
Do
| 06.03.2025 | 11:00 | 13:15 | SR 62 - Mittel frontal (MC2.Q.01.019) | Abhaltung | fix | Treatment of viral hepatitis |
| |
Do
| 06.03.2025 | 14:00 | 16:15 | SR 62 - Mittel frontal (MC2.Q.01.019) | Abhaltung | fix | The host response in COVID-19 |
| |
Do
| 06.03.2025 | 16:30 | 18:45 | SR 62 - Mittel frontal (MC2.Q.01.019) | Abhaltung | fix | Inflammatory response in sepsis and infectious disease |
| |
Fr
| 07.03.2025 | 08:30 | 10:45 | SR 62 - Mittel frontal (MC2.Q.01.019) | Abhaltung | fix | Detection and identification of bacteria |
| |
Fr
| 07.03.2025 | 11:00 | 13:15 | SR 62 - Mittel frontal (MC2.Q.01.019) | Abhaltung | fix | Fungal infections |
| |
Fr
| 07.03.2025 | 14:00 | 16:15 | SR 62 - Mittel frontal (MC2.Q.01.019) | Abhaltung | fix | Pediatric infectious diseases |
| |
Fr
| 07.03.2025 | 16:30 | 18:45 | SR 62 - Mittel frontal (MC2.Q.01.019) | Abhaltung | fix | Laboratory Diagnostics of syphilis |
| |